T. Rowe Price Associates
SGRY icon

T. Rowe Price Associates’s Surgery Partners SGRY Stock Holding History

T. Rowe Price Associates’s Portfolio SGRY Stock Details SGRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
126,064
+27,650
+28% +$388K ﹤0.01% 1975
2026
Q1 		$1.17M Buy
98,414
+11,768
+14% +$169K ﹤0.01% 2076
2025
Q4 		$1.34M Buy
86,646
+8,149
+10% +$150K ﹤0.01% 1956
2025
Q3 		$1.7M Buy
78,497
+3,092
+4% +$69K ﹤0.01% 1803
2025
Q2 		$1.68M Buy
75,405
+4,239
+6% +$94.2K ﹤0.01% 1719
2025
Q1 		$1.69M Buy
71,166
+5,022
+8% +$119K ﹤0.01% 1691
2024
Q4 		$1.4M Buy
66,144
+5,327
+9% +$140K ﹤0.01% 1814
2024
Q3 		$1.96M Sell
60,817
-319,189
-84% -$9.43M ﹤0.01% 1646
2024
Q2 		$9.04M Sell
380,006
-648,650
-63% -$16.6M ﹤0.01% 1125
2024
Q1 		$30.7M Sell
1,028,656
-79,015
-7% -$2.47M ﹤0.01% 859
2023
Q4 		$35.4M Sell
1,107,671
-449,293
-29% -$13M ﹤0.01% 793
2023
Q3 		$45.5M Buy
1,556,964
+1,921
+0.1% +$69.1K 0.01% 711
2023
Q2 		$70M Buy
1,555,043
+620,680
+66% +$23.7M 0.01% 611
2023
Q1 		$32.2M Buy
934,363
+458,864
+97% +$14.9M ﹤0.01% 804
2022
Q4 		$13.2M Sell
475,499
-164,777
-26% -$4.36M ﹤0.01% 1005
2022
Q3 		$15M Sell
640,276
-1,549,488
-71% -$49.5M ﹤0.01% 990
2022
Q2 		$63.3M Sell
2,189,764
-472,157
-18% -$20.6M 0.01% 807
2022
Q1 		$147M Sell
2,661,921
-148,159
-5% -$7.33M 0.01% 623
2021
Q4 		$150M Buy
2,810,080
+284,644
+11% +$13.2M 0.01% 640
2021
Q3 		$107M Sell
2,525,436
-160,058
-6% -$8.17M 0.01% 751
2021
Q2 		$179M Sell
2,685,494
-38,503
-1% -$2.09M 0.02% 595
2021
Q1 		$121M Buy
2,723,997
+2,716,573
+36,592% +$101M 0.01% 713
2020
Q4 		$215K Buy
+7,424
New +$185K ﹤0.01% 2536

Other funds holding SGRY

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KSCM
King Street Capital Management New York $190M AUM 16.01% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's SGRY Position: Q2 2026 in Review

T. Rowe Price Associates increased its Surgery Partners (SGRY) stake by 28% in Q2 2026, buying an estimated $388K and bringing the position to 126,064 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

T. Rowe Price Associates first reported a position in SGRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $179M in Q2 2021. 187 funds tracked by Wall St. Rank hold SGRY as of Q2 2026.

  • T. Rowe Price Associates held 126,064 shares of Surgery Partners worth $2.12M as of Q2 2026.
  • T. Rowe Price Associates bought 27,650 Surgery Partners shares in Q2 2026, an estimated $388K.
  • Surgery Partners made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1975 holding.
  • T. Rowe Price Associates first reported a position in Surgery Partners in Q4 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Surgery Partners position peaked at $179M in Q2 2021.
  • 187 funds tracked by Wall St. Rank held Surgery Partners as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.